Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 107 | 2024 | 6939 | 9.880 |
Why?
|
HIV Infections | 121 | 2024 | 16715 | 5.810 |
Why?
|
CD4-Positive T-Lymphocytes | 54 | 2024 | 4386 | 5.400 |
Why?
|
Proviruses | 21 | 2024 | 318 | 5.370 |
Why?
|
Virus Latency | 19 | 2024 | 358 | 4.600 |
Why?
|
HIV Seropositivity | 9 | 2023 | 971 | 2.510 |
Why?
|
CD8-Positive T-Lymphocytes | 42 | 2022 | 4477 | 2.390 |
Why?
|
HIV Long-Term Survivors | 9 | 2018 | 126 | 2.290 |
Why?
|
DNA, Viral | 16 | 2022 | 2226 | 2.030 |
Why?
|
Viral Load | 36 | 2024 | 3300 | 2.030 |
Why?
|
Anti-Retroviral Agents | 17 | 2023 | 1714 | 1.940 |
Why?
|
Disease Reservoirs | 8 | 2020 | 131 | 1.620 |
Why?
|
T-Lymphocyte Subsets | 8 | 2022 | 1837 | 1.300 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 365 | 1.180 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2020 | 985 | 1.130 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2024 | 789 | 1.090 |
Why?
|
Virus Replication | 16 | 2024 | 2535 | 1.060 |
Why?
|
Genome, Viral | 4 | 2020 | 665 | 1.040 |
Why?
|
Virus Integration | 5 | 2024 | 299 | 1.000 |
Why?
|
Anti-HIV Agents | 17 | 2023 | 4255 | 0.970 |
Why?
|
Receptors, HIV | 2 | 2017 | 163 | 0.970 |
Why?
|
Viremia | 14 | 2023 | 736 | 0.970 |
Why?
|
Interferon-alpha | 5 | 2024 | 895 | 0.960 |
Why?
|
Antiretroviral Therapy, Highly Active | 16 | 2019 | 1872 | 0.850 |
Why?
|
Dendritic Cells | 18 | 2023 | 2720 | 0.830 |
Why?
|
Th1 Cells | 3 | 2020 | 1057 | 0.810 |
Why?
|
Immunity, Innate | 8 | 2022 | 2961 | 0.790 |
Why?
|
T-Lymphocytes, Cytotoxic | 15 | 2022 | 1821 | 0.750 |
Why?
|
Viral Tropism | 2 | 2017 | 101 | 0.710 |
Why?
|
Immunologic Memory | 5 | 2023 | 1347 | 0.670 |
Why?
|
Phylogeny | 5 | 2022 | 2796 | 0.650 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2009 | 2232 | 0.610 |
Why?
|
AIDS Vaccines | 7 | 2017 | 938 | 0.600 |
Why?
|
Histocompatibility Antigens Class I | 10 | 2022 | 1366 | 0.580 |
Why?
|
Killer Cells, Natural | 10 | 2023 | 2131 | 0.570 |
Why?
|
Hepatitis C | 4 | 2018 | 1591 | 0.550 |
Why?
|
Hydroxamic Acids | 3 | 2016 | 494 | 0.550 |
Why?
|
HIV | 6 | 2021 | 1604 | 0.540 |
Why?
|
Evolution, Molecular | 5 | 2019 | 1940 | 0.510 |
Why?
|
Base Sequence | 8 | 2022 | 12798 | 0.510 |
Why?
|
Humans | 149 | 2024 | 743811 | 0.510 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2014 | 191 | 0.500 |
Why?
|
HIV Antibodies | 5 | 2023 | 1322 | 0.490 |
Why?
|
Ribavirin | 3 | 2018 | 394 | 0.490 |
Why?
|
Telomerase | 2 | 2010 | 731 | 0.480 |
Why?
|
Receptors, Immunologic | 6 | 2014 | 1423 | 0.480 |
Why?
|
Lymphoid Progenitor Cells | 1 | 2014 | 20 | 0.480 |
Why?
|
Lymph Nodes | 4 | 2023 | 3476 | 0.460 |
Why?
|
HIV Reverse Transcriptase | 1 | 2014 | 213 | 0.450 |
Why?
|
Leukocytes, Mononuclear | 8 | 2023 | 1836 | 0.440 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 727 | 0.430 |
Why?
|
RNA, Viral | 10 | 2023 | 2901 | 0.410 |
Why?
|
Cell Polarity | 1 | 2015 | 645 | 0.410 |
Why?
|
Monocytes | 5 | 2020 | 2593 | 0.410 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 3 | 2023 | 570 | 0.400 |
Why?
|
Receptors, CCR5 | 3 | 2021 | 498 | 0.400 |
Why?
|
Epitopes, T-Lymphocyte | 11 | 2021 | 880 | 0.400 |
Why?
|
CD4 Lymphocyte Count | 10 | 2023 | 2560 | 0.400 |
Why?
|
Telomere-Binding Proteins | 1 | 2012 | 116 | 0.390 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1832 | 0.390 |
Why?
|
Myeloid Cells | 3 | 2021 | 808 | 0.390 |
Why?
|
Antigen Presentation | 7 | 2012 | 1283 | 0.380 |
Why?
|
Indoles | 3 | 2016 | 1841 | 0.380 |
Why?
|
Botswana | 6 | 2023 | 1040 | 0.370 |
Why?
|
Ritonavir | 2 | 2003 | 322 | 0.370 |
Why?
|
HLA-B Antigens | 5 | 2016 | 354 | 0.370 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2020 | 615 | 0.360 |
Why?
|
HIV Protease Inhibitors | 2 | 2003 | 430 | 0.350 |
Why?
|
Daptomycin | 1 | 2009 | 73 | 0.340 |
Why?
|
Heterochromatin | 2 | 2023 | 296 | 0.340 |
Why?
|
Th17 Cells | 1 | 2015 | 766 | 0.330 |
Why?
|
Antiviral Agents | 6 | 2023 | 2984 | 0.330 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 705 | 0.330 |
Why?
|
Flow Cytometry | 11 | 2017 | 5973 | 0.330 |
Why?
|
Stem Cells | 4 | 2019 | 3566 | 0.330 |
Why?
|
Transcription, Genetic | 2 | 2022 | 7719 | 0.320 |
Why?
|
Glycopeptides | 1 | 2009 | 226 | 0.320 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2014 | 952 | 0.310 |
Why?
|
Phenotype | 2 | 2023 | 16361 | 0.310 |
Why?
|
HLA-A3 Antigen | 2 | 2006 | 34 | 0.300 |
Why?
|
Chromosomes, Human | 2 | 2019 | 457 | 0.290 |
Why?
|
Toll-Like Receptor 9 | 2 | 2019 | 211 | 0.290 |
Why?
|
Virus Activation | 3 | 2020 | 319 | 0.290 |
Why?
|
Simian immunodeficiency virus | 3 | 2023 | 846 | 0.280 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 71 | 0.280 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 1978 | 0.280 |
Why?
|
Adult | 53 | 2023 | 213889 | 0.280 |
Why?
|
Middle Aged | 46 | 2022 | 213241 | 0.260 |
Why?
|
Endocarditis, Bacterial | 1 | 2009 | 455 | 0.260 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5445 | 0.250 |
Why?
|
Cell Survival | 6 | 2023 | 5881 | 0.250 |
Why?
|
Cell Proliferation | 8 | 2024 | 10477 | 0.250 |
Why?
|
Genes, nef | 1 | 2004 | 55 | 0.250 |
Why?
|
Hemophilia B | 1 | 2005 | 81 | 0.250 |
Why?
|
Down-Regulation | 1 | 2012 | 3000 | 0.240 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2014 | 1369 | 0.240 |
Why?
|
Female | 57 | 2023 | 380020 | 0.230 |
Why?
|
Immunity, Cellular | 5 | 2015 | 1608 | 0.230 |
Why?
|
Male | 53 | 2023 | 349776 | 0.230 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 805 | 0.230 |
Why?
|
Leukocytes | 1 | 2011 | 2044 | 0.230 |
Why?
|
Receptors, Interleukin-21 | 1 | 2023 | 33 | 0.220 |
Why?
|
Receptors, Chemokine | 2 | 2007 | 670 | 0.220 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3591 | 0.220 |
Why?
|
Interleukins | 3 | 2017 | 791 | 0.220 |
Why?
|
Interferon-gamma | 7 | 2015 | 3205 | 0.220 |
Why?
|
Mozambique | 1 | 2022 | 54 | 0.220 |
Why?
|
Liver Failure | 1 | 2005 | 241 | 0.220 |
Why?
|
Alleles | 7 | 2022 | 6934 | 0.210 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 153 | 0.210 |
Why?
|
Membrane Glycoproteins | 6 | 2014 | 3769 | 0.210 |
Why?
|
Ionomycin | 1 | 2022 | 109 | 0.210 |
Why?
|
Drug Resistance, Bacterial | 1 | 2009 | 1030 | 0.210 |
Why?
|
Sarcoma, Kaposi | 1 | 2005 | 370 | 0.210 |
Why?
|
Indinavir | 1 | 2002 | 74 | 0.210 |
Why?
|
Sequence Analysis, DNA | 3 | 2022 | 4803 | 0.200 |
Why?
|
B-Lymphocyte Subsets | 1 | 2023 | 246 | 0.200 |
Why?
|
Hemophilia A | 1 | 2005 | 351 | 0.200 |
Why?
|
Gene Products, gag | 4 | 2007 | 337 | 0.200 |
Why?
|
Delusions | 1 | 2024 | 300 | 0.200 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2020 | 215 | 0.200 |
Why?
|
Cyclin-Dependent Kinase 9 | 2 | 2011 | 66 | 0.200 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2005 | 690 | 0.190 |
Why?
|
Antigens, CD | 6 | 2015 | 4026 | 0.190 |
Why?
|
Molecular Sequence Data | 13 | 2014 | 18107 | 0.190 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2022 | 821 | 0.190 |
Why?
|
Basal Ganglia | 1 | 2023 | 546 | 0.190 |
Why?
|
Infant, Newborn | 6 | 2023 | 25609 | 0.190 |
Why?
|
Species Specificity | 4 | 2014 | 2480 | 0.190 |
Why?
|
Genes, MHC Class I | 4 | 2010 | 258 | 0.180 |
Why?
|
Staphylococcal Infections | 1 | 2009 | 1400 | 0.180 |
Why?
|
Lymphocyte Activation | 5 | 2020 | 5524 | 0.180 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2000 | 143 | 0.180 |
Why?
|
Up-Regulation | 4 | 2014 | 4221 | 0.180 |
Why?
|
HLA Antigens | 3 | 2011 | 1382 | 0.180 |
Why?
|
Lectins, C-Type | 1 | 2003 | 589 | 0.180 |
Why?
|
Acute Disease | 7 | 2019 | 7150 | 0.170 |
Why?
|
Gene Expression Profiling | 5 | 2020 | 9440 | 0.170 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2000 | 227 | 0.170 |
Why?
|
Cells, Cultured | 8 | 2020 | 19232 | 0.170 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2021 | 1320 | 0.170 |
Why?
|
Lymphocyte Subsets | 2 | 2014 | 315 | 0.170 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 173 | 0.170 |
Why?
|
Pyrimidinones | 2 | 2019 | 370 | 0.160 |
Why?
|
Amino Acid Sequence | 13 | 2014 | 13809 | 0.160 |
Why?
|
Doxorubicin | 1 | 2005 | 2234 | 0.160 |
Why?
|
Helicobacter pylori | 1 | 2002 | 384 | 0.160 |
Why?
|
Helicobacter Infections | 1 | 2002 | 388 | 0.160 |
Why?
|
Antigens, CD34 | 1 | 2000 | 658 | 0.160 |
Why?
|
Clone Cells | 1 | 2022 | 1692 | 0.160 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 656 | 0.160 |
Why?
|
Germinal Center | 1 | 2020 | 377 | 0.150 |
Why?
|
Hepatitis C, Chronic | 2 | 2002 | 1029 | 0.150 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2020 | 4422 | 0.140 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4183 | 0.140 |
Why?
|
Fatty Liver | 1 | 2003 | 728 | 0.140 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 1602 | 0.140 |
Why?
|
Interferons | 2 | 2022 | 706 | 0.140 |
Why?
|
Biological Evolution | 1 | 2022 | 1079 | 0.130 |
Why?
|
Integrins | 1 | 2000 | 846 | 0.130 |
Why?
|
Gene Silencing | 2 | 2020 | 1537 | 0.130 |
Why?
|
Gene Products, nef | 2 | 2006 | 110 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 847 | 0.130 |
Why?
|
Aged | 16 | 2022 | 163178 | 0.130 |
Why?
|
Vaccines, Subunit | 2 | 2014 | 168 | 0.130 |
Why?
|
Young Adult | 11 | 2020 | 56392 | 0.130 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4931 | 0.120 |
Why?
|
Reverse Transcription | 1 | 2014 | 47 | 0.120 |
Why?
|
Caspase 8 | 1 | 2014 | 195 | 0.120 |
Why?
|
T-Lymphocytes | 3 | 2017 | 10179 | 0.120 |
Why?
|
Cohort Studies | 14 | 2018 | 40545 | 0.120 |
Why?
|
HIV Antigens | 2 | 2005 | 347 | 0.120 |
Why?
|
DNA | 2 | 2019 | 7295 | 0.120 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 783 | 0.120 |
Why?
|
Enzyme Stability | 1 | 2014 | 210 | 0.120 |
Why?
|
Depsipeptides | 1 | 2014 | 94 | 0.120 |
Why?
|
Immunodominant Epitopes | 5 | 2006 | 267 | 0.120 |
Why?
|
South Africa | 1 | 2019 | 1731 | 0.120 |
Why?
|
Toll-Like Receptor 1 | 1 | 2013 | 48 | 0.120 |
Why?
|
Cell Count | 2 | 2015 | 1855 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2007 | 2540 | 0.120 |
Why?
|
Host-Pathogen Interactions | 3 | 2021 | 1479 | 0.120 |
Why?
|
Phosphopeptides | 1 | 2014 | 241 | 0.110 |
Why?
|
Disease Progression | 8 | 2017 | 13273 | 0.110 |
Why?
|
Lipopeptides | 1 | 2013 | 75 | 0.110 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 2865 | 0.110 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 504 | 0.110 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 1181 | 0.110 |
Why?
|
HLA-DR Antigens | 2 | 2012 | 645 | 0.100 |
Why?
|
Liver | 2 | 2005 | 7479 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2020 | 6170 | 0.100 |
Why?
|
Rectum | 1 | 2017 | 904 | 0.100 |
Why?
|
Genotype | 4 | 2021 | 12944 | 0.100 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 127 | 0.100 |
Why?
|
Epigenesis, Genetic | 2 | 2022 | 3645 | 0.100 |
Why?
|
Time Factors | 6 | 2019 | 40038 | 0.100 |
Why?
|
Toll-Like Receptor 2 | 1 | 2013 | 354 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7172 | 0.100 |
Why?
|
Drug Therapy, Combination | 5 | 2006 | 6487 | 0.100 |
Why?
|
RNA, Small Interfering | 4 | 2015 | 3504 | 0.100 |
Why?
|
Nevirapine | 2 | 2023 | 267 | 0.100 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2014 | 1574 | 0.100 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 371 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2014 | 21733 | 0.090 |
Why?
|
Infant | 5 | 2023 | 35122 | 0.090 |
Why?
|
Histone Deacetylases | 1 | 2015 | 727 | 0.090 |
Why?
|
DNA Primers | 3 | 2011 | 2891 | 0.090 |
Why?
|
RNA, Messenger | 4 | 2011 | 13028 | 0.090 |
Why?
|
Genetic Variation | 4 | 2019 | 6535 | 0.090 |
Why?
|
Receptors, CXCR5 | 2 | 2023 | 92 | 0.090 |
Why?
|
Th2 Cells | 1 | 2015 | 1061 | 0.090 |
Why?
|
Chromatin | 1 | 2022 | 2931 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1580 | 0.090 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2009 | 0.090 |
Why?
|
Cytokines | 5 | 2017 | 7324 | 0.090 |
Why?
|
Prospective Studies | 4 | 2023 | 53250 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2014 | 1880 | 0.080 |
Why?
|
HLA-A Antigens | 2 | 2006 | 232 | 0.080 |
Why?
|
Oxazines | 2 | 2020 | 298 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2013 | 1186 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2883 | 0.080 |
Why?
|
HLA-B27 Antigen | 1 | 2007 | 76 | 0.080 |
Why?
|
Disease Transmission, Infectious | 1 | 2013 | 546 | 0.080 |
Why?
|
Apoptosis | 2 | 2018 | 9718 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3389 | 0.080 |
Why?
|
RNA Polymerase II | 1 | 2011 | 548 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1419 | 0.070 |
Why?
|
Mutation | 7 | 2021 | 29777 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2014 | 2712 | 0.070 |
Why?
|
Drug Resistance, Viral | 2 | 2021 | 820 | 0.070 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 999 | 0.070 |
Why?
|
Phosphorylation | 2 | 2014 | 8436 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4749 | 0.070 |
Why?
|
Cell Degranulation | 1 | 2007 | 287 | 0.070 |
Why?
|
B-Lymphocytes | 4 | 2020 | 4665 | 0.070 |
Why?
|
Intestinal Mucosa | 1 | 2017 | 3038 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2019 | 13980 | 0.070 |
Why?
|
Diseases in Twins | 1 | 2007 | 450 | 0.060 |
Why?
|
Pyridones | 2 | 2020 | 711 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3750 | 0.060 |
Why?
|
Child | 5 | 2023 | 77637 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 213 | 0.060 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2005 | 159 | 0.060 |
Why?
|
Viral Structural Proteins | 1 | 2004 | 103 | 0.060 |
Why?
|
Cross Reactions | 1 | 2006 | 841 | 0.060 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 675 | 0.060 |
Why?
|
Ligands | 2 | 2008 | 3281 | 0.060 |
Why?
|
Lamivudine | 2 | 2021 | 342 | 0.060 |
Why?
|
Gene Expression Regulation | 4 | 2020 | 12066 | 0.060 |
Why?
|
Signal Transduction | 4 | 2021 | 23398 | 0.060 |
Why?
|
Interleukin-12 | 2 | 2020 | 577 | 0.060 |
Why?
|
Immunoglobulin D | 1 | 2023 | 56 | 0.060 |
Why?
|
Zidovudine | 2 | 2021 | 620 | 0.060 |
Why?
|
RNA | 2 | 2023 | 2748 | 0.060 |
Why?
|
Interleukin-2 | 2 | 2014 | 1904 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2006 | 1793 | 0.060 |
Why?
|
Hepatomegaly | 1 | 2003 | 85 | 0.060 |
Why?
|
HIV-2 | 1 | 2023 | 167 | 0.060 |
Why?
|
Genes, Viral | 1 | 2004 | 718 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 184 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1157 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2258 | 0.050 |
Why?
|
Receptors, CCR1 | 1 | 2002 | 33 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2453 | 0.050 |
Why?
|
RNA Interference | 1 | 2011 | 2890 | 0.050 |
Why?
|
Chemokine CCL3 | 1 | 2002 | 84 | 0.050 |
Why?
|
Lung Diseases, Fungal | 1 | 2003 | 122 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2002 | 112 | 0.050 |
Why?
|
Chemokine CCL4 | 1 | 2002 | 129 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2002 | 123 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
Telomere | 1 | 2008 | 910 | 0.050 |
Why?
|
Receptors, CCR4 | 1 | 2002 | 81 | 0.050 |
Why?
|
Mitochondria, Liver | 1 | 2003 | 187 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7793 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Tandem Repeat Sequences | 1 | 2003 | 185 | 0.050 |
Why?
|
Transaminases | 1 | 2003 | 200 | 0.050 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 222 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2017 | 25032 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2019 | 2375 | 0.050 |
Why?
|
Receptors, CXCR3 | 2 | 2017 | 237 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2002 | 209 | 0.050 |
Why?
|
Liposomes | 1 | 2005 | 759 | 0.050 |
Why?
|
Caspase 3 | 1 | 2004 | 758 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3608 | 0.050 |
Why?
|
Argentina | 1 | 2021 | 232 | 0.050 |
Why?
|
Nucleotidyltransferases | 1 | 2022 | 220 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6098 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9310 | 0.050 |
Why?
|
HIV Core Protein p24 | 2 | 2014 | 256 | 0.050 |
Why?
|
Caspases | 1 | 2004 | 928 | 0.050 |
Why?
|
Animals | 7 | 2023 | 168660 | 0.050 |
Why?
|
DNA, Satellite | 1 | 2020 | 69 | 0.050 |
Why?
|
Linear Models | 3 | 2016 | 5952 | 0.050 |
Why?
|
Integrin alpha4beta1 | 1 | 2000 | 121 | 0.050 |
Why?
|
STAT4 Transcription Factor | 1 | 2020 | 96 | 0.050 |
Why?
|
Epitopes | 4 | 2010 | 2570 | 0.050 |
Why?
|
Transcription Initiation Site | 1 | 2020 | 196 | 0.040 |
Why?
|
Mycoses | 1 | 2003 | 376 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 193 | 0.040 |
Why?
|
Culicidae | 1 | 2020 | 104 | 0.040 |
Why?
|
Substrate Specificity | 1 | 2004 | 1802 | 0.040 |
Why?
|
Nausea | 1 | 2003 | 674 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17439 | 0.040 |
Why?
|
Vomiting | 1 | 2003 | 636 | 0.040 |
Why?
|
Germany | 1 | 2002 | 862 | 0.040 |
Why?
|
CREB-Binding Protein | 1 | 2019 | 151 | 0.040 |
Why?
|
Drug Design | 1 | 2005 | 1075 | 0.040 |
Why?
|
Remission Induction | 1 | 2005 | 2384 | 0.040 |
Why?
|
Alkynes | 1 | 2020 | 305 | 0.040 |
Why?
|
Centromere | 1 | 2020 | 220 | 0.040 |
Why?
|
Piperazines | 2 | 2020 | 2487 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2018 | 6620 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2020 | 367 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 2988 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 184 | 0.040 |
Why?
|
Surface Properties | 1 | 2002 | 1168 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39001 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2019 | 63042 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 480 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 415 | 0.040 |
Why?
|
Benzoxazines | 1 | 2020 | 301 | 0.040 |
Why?
|
Defective Viruses | 1 | 2018 | 112 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 3874 | 0.040 |
Why?
|
Algorithms | 2 | 2020 | 13869 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2012 | 12020 | 0.040 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2017 | 27 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 707 | 0.040 |
Why?
|
Endothelium | 1 | 2000 | 777 | 0.040 |
Why?
|
Glycosylation | 1 | 2020 | 1129 | 0.040 |
Why?
|
Lactic Acid | 1 | 2003 | 1131 | 0.040 |
Why?
|
Cercocebus atys | 1 | 2017 | 12 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2000 | 648 | 0.040 |
Why?
|
Child, Preschool | 4 | 2022 | 40964 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15518 | 0.040 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 109 | 0.040 |
Why?
|
Glycolysis | 1 | 2021 | 830 | 0.040 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2017 | 82 | 0.040 |
Why?
|
Spain | 1 | 2018 | 464 | 0.040 |
Why?
|
Magnesium | 1 | 2000 | 813 | 0.040 |
Why?
|
Viral Proteins | 1 | 2004 | 1899 | 0.040 |
Why?
|
Brain | 1 | 2023 | 26345 | 0.040 |
Why?
|
Leukemia, T-Cell | 1 | 2017 | 104 | 0.040 |
Why?
|
Receptors, CCR6 | 1 | 2017 | 81 | 0.040 |
Why?
|
Peptides | 2 | 2010 | 4406 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2000 | 1342 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2013 | 77410 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2030 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2003 | 1064 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2016 | 130 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5179 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1851 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 590 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2018 | 765 | 0.030 |
Why?
|
Ubiquitins | 1 | 2017 | 384 | 0.030 |
Why?
|
Cyclin A | 1 | 2014 | 60 | 0.030 |
Why?
|
Outpatients | 1 | 2003 | 1488 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 1958 | 0.030 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2015 | 518 | 0.030 |
Why?
|
Pregnancy | 3 | 2021 | 29140 | 0.030 |
Why?
|
beta Catenin | 1 | 2019 | 1060 | 0.030 |
Why?
|
Cell Line | 2 | 2020 | 15993 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 782 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2017 | 844 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2359 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2014 | 120 | 0.030 |
Why?
|
Epitope Mapping | 2 | 2005 | 311 | 0.030 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2014 | 143 | 0.030 |
Why?
|
Chronic Disease | 2 | 2005 | 9139 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2000 | 3144 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2018 | 599 | 0.030 |
Why?
|
Adolescent | 3 | 2013 | 85729 | 0.030 |
Why?
|
Bystander Effect | 1 | 2013 | 81 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2017 | 1098 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4326 | 0.030 |
Why?
|
Calibration | 1 | 2014 | 816 | 0.030 |
Why?
|
Vaccines, Synthetic | 1 | 2014 | 634 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2794 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2019 | 11478 | 0.020 |
Why?
|
Biopsy | 1 | 2003 | 6750 | 0.020 |
Why?
|
Hepacivirus | 1 | 2018 | 1378 | 0.020 |
Why?
|
Survival Rate | 1 | 2005 | 12786 | 0.020 |
Why?
|
Necrosis | 1 | 2014 | 1642 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1656 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8337 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2166 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2020 | 3024 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1620 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8660 | 0.020 |
Why?
|
Solubility | 1 | 2010 | 1088 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1520 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2014 | 3701 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2027 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19894 | 0.020 |
Why?
|
Protein Binding | 1 | 2000 | 9377 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2177 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3772 | 0.020 |
Why?
|
Comorbidity | 1 | 2002 | 10380 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2005 | 15526 | 0.020 |
Why?
|
Stavudine | 1 | 2006 | 85 | 0.020 |
Why?
|
Antigenic Variation | 1 | 2006 | 125 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 6476 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2013 | 1781 | 0.020 |
Why?
|
Twins, Monozygotic | 1 | 2007 | 458 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3337 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2005 | 36 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 39 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4552 | 0.020 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2004 | 26 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 378 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14714 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2134 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2020 | 57744 | 0.020 |
Why?
|
Mass Screening | 1 | 2020 | 5251 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5216 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7908 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 2006 | 741 | 0.020 |
Why?
|
Scedosporium | 1 | 2003 | 7 | 0.010 |
Why?
|
Aspergillus niger | 1 | 2003 | 17 | 0.010 |
Why?
|
Aspergillus flavus | 1 | 2003 | 14 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10629 | 0.010 |
Why?
|
Aspergillus | 1 | 2003 | 85 | 0.010 |
Why?
|
Lung | 1 | 2022 | 9858 | 0.010 |
Why?
|
Fusarium | 1 | 2003 | 50 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2005 | 793 | 0.010 |
Why?
|
Thermodynamics | 1 | 2004 | 595 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2014 | 5096 | 0.010 |
Why?
|
Aspergillus fumigatus | 1 | 2003 | 150 | 0.010 |
Why?
|
Vaccination | 1 | 2014 | 3275 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5714 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2005 | 1202 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 235 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2003 | 768 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2004 | 1524 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 20121 | 0.010 |
Why?
|
Autopsy | 1 | 2003 | 1020 | 0.010 |
Why?
|
Selection, Genetic | 1 | 2004 | 914 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 12788 | 0.010 |
Why?
|
China | 1 | 2004 | 2243 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4974 | 0.010 |
Why?
|
Liver Diseases | 1 | 2002 | 1253 | 0.010 |
Why?
|
Risk Factors | 1 | 2020 | 72252 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9272 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12354 | 0.010 |
Why?
|
Pilot Projects | 1 | 2002 | 8316 | 0.010 |
Why?
|